HomeInsightsEPS

Remus Pharmaceuticals Ltd EPS

Remus Pharmaceuticals Ltd EPS

stocks purchased

₹ 0.5 Cr

Volume Transacted

()

stocks purchased

2.1 K

Stocks Traded

()

Last Updated on: Nov 08, 2024

Image

Remus Pharmaceuticals Ltd

NSE: RemusPharma.

EPS

₹ 34.52

Last updated on: Nov 07, 2024

Key Highlights

  • The Earning per Share of Remus Pharmaceuticals Ltd is ₹ 34.52 as of 07 Nov 24.

Market Price Over Time

1M

1Y

3Y

5Y

Monitoring Remus Pharmaceuticals Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
07 Nov 20242480
06 Nov 20242529.45
05 Nov 20242544.55
04 Nov 20242542.6
01 Nov 20242632.3
31 Oct 20242616.7
30 Oct 20242598.75
29 Oct 20242571.45
28 Oct 20242441
25 Oct 20242404.75

SWOT Analysis Of Remus Pharmaceuticals Ltd

Strength

4

S

Weakness

3

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Remus Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Remus Pharmaceuticals Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Historical Market Cap of Remus Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Revenue of Remus Pharmaceuticals Ltd

No data available

* All values are in crore

Historical EBITDA of Remus Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Net Profit of Remus Pharmaceuticals Ltd

No data available

* All values are in crore

Dividend Payout Over Time

No data available

Remus Pharmaceuticals Ltd News Hub

News

Remus Pharmaceuticals to convene board meeting

Remus Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 9 No...

Read more

07 Nov 202410:21

News

Remus Pharmaceuticals to convene AGM

Remus Pharmaceuticals announced that the 9th Annual General Meeting (AGM) of the company w...

Read more

31 Aug 202415:40

News

Remus Pharmaceuticals to table results

Remus Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 16 M...

Read more

10 May 202412:07

News

Remus Pharmaceuticals schedules EGM

Remus Pharmaceuticals announced that an Extra Ordinary General Meeting (EGM) of the Compan...

Read more

24 Apr 202410:34

News

Remus Pharmaceuticals revises board meeting date

Remus Pharmaceuticals has revised the meeting of the Board of Directors which was schedule...

Read more

20 Apr 202415:16

News

Remus Pharmaceuticals to consider Dividend

Remus Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 22 A...

Read more

17 Apr 202409:39

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for EPS of Remus Pharmaceuticals Ltd

What is the EPS of Remus Pharmaceuticals Ltd stock?

The Earnings Per Share (EPS) of Remus Pharmaceuticals Ltd is 0.0. An EPS is the amount of net income attributed to each share of a common stock.

How is Remus Pharmaceuticals Ltd EPS calculated?

The EPS of Remus Pharmaceuticals Ltd is calculated by dividing the net income by the number of outstanding shares. The formula is EPS = (Net Income - Dividends on Preferred Stock) / Average Outstanding Shares.

How often does Remus Pharmaceuticals Ltd report its EPS?

Remus Pharmaceuticals Ltd typically reports its EPS quarterly and annually, in conjunction with its financial statements and earnings reports.

What factors can influence Remus Pharmaceuticals Ltd EPS?

Factors that influence the EPS of Remus Pharmaceuticals Ltd include revenue changes, cost fluctuations, operational efficiency, tax rates, and one-time gains or losses.

Can Remus Pharmaceuticals Ltd EPS growth indicate future performance?

Yes, consistent growth in Remus Pharmaceuticals Ltd EPS can suggest strong financial health and effective management, potentially indicating positive future performance.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*